|Last Price||Today's Change||52-Week Range||Trading Volume|
|50.65||0.11 (+0.22%)||41.32 - 57.49||4.0 million|
Market data as of 4:00PM 08/29/14. Quotes are delayed by at least 15 min.
Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE)
08/30/2014 5:15 AM ET
U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
08/21/2014 1:31 PM ET